Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.
Reference facts
- Also known as
- Mounjaro, Zepbound, LY3298176
- Category
- GLP-1 & Metabolic
- Mechanism of action
- Dual GIP / GLP-1 receptor agonist. Enhances glucose-dependent insulin secretion, slows gastric emptying, and improves adipocyte fatty-acid handling.
- Targets
- GIPR, GLP-1R
- Indications under research or approved
- Type 2 Diabetes, Obesity, Obstructive Sleep Apnea (OSA)
- Regulatory status (reference entry)
- FDA-approved (Mounjaro 2022 for T2D; Zepbound 2023 for chronic weight management; OSA 2024)
- Half-life
- ~120 hours (~5 days)
- Sequence
- YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
- Sequence notes
- 39-residue dual GIP/GLP-1 agonist with Aib at positions 2 and 13 (X) and a C20 fatty diacid linker at Lys20.
- Molecular weight (Da)
- 4814
- PDB accession
- 7RTI
- Originator / sponsor
- Eli Lilly
- First reported
- 2018
- Origin
- Disclosed by Eli Lilly in 2018 as a unimolecular dual incretin.
Primary References
- SURPASS-2 — Tirzepatide vs Semaglutide in T2D, NEJM 2021
- SURMOUNT-1 — Tirzepatide for obesity, NEJM 2022
- FDA Mounjaro label
Explore research articles about Tirzepatide
This is an educational reference, not medical advice. Research findings do not establish safety or efficacy for self-administration. Consult the primary sources for study populations, limitations, and current regulatory status.